Recursion Pharmaceuticals (RXRX) Stock Analysis & Winston Score

Recursion Pharmaceuticals is a biotechnology company that uses artificial intelligence and large-scale lab automation to discover new drugs. Instead of testing drug candidates one at a time the traditional way, it runs millions of biological experiments and feeds the data into AI models to find potential treatments faster. The company is working on drugs for rare genetic diseases, cancer, and infectious diseases, and it partners with large pharmaceutical companies like Roche and Bayer to help them find new medicines too. Recursion makes money through a mix of partnership deals, milestone payments, and research collaborations with big pharma companies, while also advancing its own drug pipeline. It is headquartered in Salt Lake City, Utah, and operates primarily in the United States with a growing global data and computing footprint. The company is not yet profitable and burns significant cash each year, so its biggest risk is whether its AI-driven approach will produce approved drugs before it needs to raise more money from investors.